CSIMarket
 
Altimmune inc   (NASDAQ: ALT)
 
Price: $3.2450 $-0.04 -1.067%
Day's High: $3.319999933242798 Week Perf: 4.34 %
Day's Low: $ 3.22 30 Day Perf: 7.1 %
Volume (M): 838,731 52 Wk High: $ 6.44
Volume (M$): $ 0 52 Wk Avg: $3.70
Open: $3.30 52 Wk Low: $2.56



 Market Capitalization (Millions $) 602
 Shares Outstanding (Millions) 185
 Employees 57
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -92
 Cash Flow (TTM) (Millions $) -86
 Capital Exp. (TTM) (Millions $) 0

Business Description


Altimmune Inc is a clinical-stage biopharmaceutical company that specializes in developing and commercializing therapies for the treatment of infectious diseases, immunological disorders, and liver diseases. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Altimmune uses a proprietary technology platform, called RespirVec, to develop its vaccines and immunotherapies. RespirVec is a respiratory virus-based vector system that enables the efficient delivery of antigens directly to the immune system, resulting in a robust immune response. The platform is highly versatile, with the ability to deliver a wide range of vaccine candidates and therapeutic proteins.

One of Altimmune's lead programs is the development of a single-dose, intranasal COVID-19 vaccine candidate, AdCOVID. This vaccine uses Altimmunees RespirVec technology to deliver the spike protein antigen of SARS-CoV-2, the virus that causes COVID-19. The company is currently conducting Phase 1 trials for AdCOVID, and is confident that the vaccine will be effective in preventing COVID-19, both in the initial pandemic and in future waves.

Altimmune has a robust pipeline of other infectious disease programs, including a hepB vaccine, a flu vaccine, and an anthrax vaccine. The company is also developing immunotherapies for chronic hepatitis B, Alpha-1 Antitrypsin Deficiency, and NASH (non-alcoholic steatohepatitis).

Altimmune maintains partnerships and collaborations with other leading biopharmaceutical companies, including the University of Alabama at Birmingham, the University of Maryland School of Medicine, and the University of North Carolina at Chapel Hill. These collaborations give Altimmune access to world-class research facilities, expertise, and resources.

Overall, Altimmune Inc is a cutting-edge biopharmaceutical company that is at the forefront of developing innovative therapies for some of the world's most pressing health issues. With its strong pipeline, proprietary technology platform, and collaborative approach, Altimmune is well-suited to continue making significant contributions to the field of biopharmaceuticals.


   Company Address: 910 Clopper Road Gaithersburg 20878 MD
   Company Phone Number: 654-1450   Stock Exchange / Ticker: NASDAQ ALT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        1.07% 
BMY        1.09% 
EBS        3.86% 
OPK        12.67% 
PFE        2.48% 
REGN        4.86% 
• View Complete Report
   



Clinical Study

AI-Powered Pathology Drives Promising Advancements in Altimmunes Liver Fibrosis Trial,

Published Fri, Nov 7 2025 1:46 PM UTC

AI-Based Pathology Unveils Promising Results in Liver Fibrosis from Pemvidutide IMPACT Phase 2b Trial The field of hepatic diseases has long sought innovative approaches to tackle the persistent challenge of liver fibrosis, especially in the context of Metabolic Associated Steatohepatitis (MASH). At the forefront of this pursuit, Altimmune presented compelling results from t...

Clinical Study

Advancements in Non-Alcoholic Steatohepatitis Management Altimmunes Pemvidutide Phase 2b Results and Financial Stand...

Published Mon, Oct 20 2025 12:05 PM UTC

Recent developments in the treatment of non-alcoholic steatohepatitis (NASH) highlight the increasing potential of emerging therapies. Notably, Altimmune Inc. is poised to present compelling findings from its Phase 2b clinical trial of Pemvidutide, a novel therapeutic candidate for managing moderate to severe alcohol-related liver disease. This presentation will take place d...

Announcement

Navigating Legal and Market Challenges Altimmune Inc. Faces Investor Scrutiny Amidst Revenue Stagnation

Published Mon, Sep 22 2025 4:08 AM UTC

The pharmaceutical industry is a dynamic and competitive arena, with significant implications for investors and stakeholders. Altimmune, Inc. (NASDAQ: ALT), a notable entity within this sector, has recently come under scrutiny due to a combination of legal concerns and stagnant revenue performance. This article explores these challenges in detail, sheds light on their implic...

Announcement

Investor Alert Legal Challenges Loom for Altimmune and SelectQuote Amidst Mixed Financial Signals

Published Fri, Sep 19 2025 4:37 PM UTC

In a noteworthy development for investors, Bragar Eagel & Squire, P.C., a prominent shareholder rights law firm, has issued a reminder regarding ongoing class action lawsuits against Altimmune, Inc. (NASDAQ: ALT) and SelectQuote, Inc. (NYSE: SLQT). Stockholders of these companies are encouraged to act swiftly, as the deadlines for petitioning the court to become lead plainti...

Announcement

Altimmune Inc. A Cautionary Tale of Declining Revenues and Legal Woes in the Biopharmaceutical Sector

Published Mon, Sep 8 2025 9:01 AM UTC

Analyzing the Current LandscapeIn recent developments, Altimmune, Inc. (NASDAQ: ALT) has found itself navigating turbulent waters. The company, known for its innovative approaches in the biopharmaceutical sector, has recently faced a class action lawsuit, leading to significant investor attention and concern. The Pomerantz Law Firm has stepped in, reminding investors who ha...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 19,411.77
Price to Sales (Expected) -
Price to Book 1.27
PEG (TTM) -

Financial Strength Current
Quick Ratio 62.54
Working Capital Ratio 63.48
Leverage Ratio (MRQ) 0.11
Total Debt to Equity 0.07
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.82 $
Revenues (TTM) 0 $
Cash Flow (TTM) -
Cash 4.22 $
Book Value 2.56 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,609,825
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.